A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects with Treatment-Resistant Depression
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2014
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Janssen-Cilag
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Feb 2013 Planned End Date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.